Anavex Life Sciences Corp (AVXL)

[blu_1]

Flurizan was an amyloid reducing drug. Everyone now knows that approach sucks. Alzheimers is a mitochondrial dysfunction disease. Only 1 drug in clinical trials addresses that - Anavex 2-73. That is what makes 2-73 neuroprotective, not just neurorestorative (cough bryostatin). 2-73's safety profile can't be touched by the competition. The current 2-73 trial is Ph 2a. It's not the same as Ph 2b or Ph 3. Its patients have mild TO MODERATE Alzheimer's Disease. The patients in this trial aren't on optimized dosages. This is a small trial not powered for statistical significance, tho a bunch of the results have been statistically significant. Dr George Perry of the Alzheimers Journal said 2-73's scores are the best he's ever seen, better than Flurizan, donepezil, and bryostatin.